LianBio Investor Relations

LianBio (NASDAQ: LIAN) is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in Greater China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio’s model leverages a number of key elements, including transformative in-licensing, development and commercialization approaches designed to deliver innovative therapeutic solutions to patients. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.